Advertisement

BMC Pharmacology

, 5:P28 | Cite as

Phosphodiestrase 5 and effects of sildenafil on cerebral arteries from man and guinea pig

  • Christina Kruuse
  • Tejvir S Khurana
  • Sergei D Rybalkin
  • Steffen Birk
  • Ulla Engel
  • Lars Edvinsson
  • Jes Olesen
Open Access
Poster presentation
  • 1.7k Downloads

Keywords

Migraine Sodium Nitroprusside Effective Plasma Concentration Endothelial Removal cGMP Hydrolysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Background

The specific inhibitor of the cGMP degrading enzyme phosphodiesterase 5 (PDE5), sildenafil (Viagra®), induces migraine without significant cerebral artery dilatation in vivo. This is in contrast to other migraine inducing substances such as glyceryl trinitrate and histamine which are effective vasodilators. Sildenafil is also recently found to enhance functional recovery, neurogenesis and angiogenesis in stroke models. We evaluated the presence of PDE5 and functional effects of three selective PDE inhibitors in human and guinea pig cerebral arteries.

Materials and methods

RT-PCR and Western blot were used to establish the presence of PDE5 mRNA and protein respectively. The effects of sildenafil, UK-114,542 (both PDE5 specific) and UK-90,234 (PDE1 specific) on cyclic nucleotide hydrolysis were investigated using homogenates of human and guinea pig cerebral arteries. In isolated guinea pig basilar arteries the cerebral vasodilator responses of the PDE inhibitors were investigated. Concomitantly the tissue levels of cAMP and cGMP were analysed.

Results

PDE5A mRNA and protein were present in human middle cerebral artery. Sildenafil and UK-114,542 caused a concentration-dependent inhibition of cGMP hydrolysis. Sildenafil induced an endothelium dependent vasodilatation (pEC50 6.0 ± 0.3), which was less than 10 % of maximal dilatation within the clinically effective plasma concentrations after oral sildenafil 100 mg (40 nM) (See figure 1). The dilatation was augmented by sodium nitroprusside (SNP) pre-treatment. UK-114,542 (pEC50 8.6 ± 0.1) was a more potent vasodilator than sildenafil. The PDE1 inhibitor UK-90,234 elicited a non-specific response with poor potency (pEC50 5.2 ± 0.1). The vasodilatation was attenuated by endothelial removal or pharmacological inhibition of endogenous cGMP production, but a cGMP-independent dilatory response was seen at high concentrations.
Figure 1

Concentration-response curve for UK-90,234 (square), UK-114,542 (circle) and sildenafil (triangle) without (filled symbols) and with (open symbols) pre-treatment with the inhibitor of soluble guanylate cyclase, ODQ (10 μM), in intact arteries. Relaxation is given as % relaxation of pre-contraction and each point shows mean ± S.E.M. In high concentrations all compounds elicited a small cGMP-independent dilatory response.

Conclusion

Sildenafil in vitro mainly dilates cerebral arteries above relevant plasma concentrations of sildenafil, unless a nitric oxide donor is co-administered. These results supports the lack of vascular response previously found in human in vivo studies and may suggest a possible neuronal rather than vascular effect of sildenafil in migraine induction.

Copyright information

© BioMed Central Ltd 2005

Authors and Affiliations

  • Christina Kruuse
    • 1
    • 2
  • Tejvir S Khurana
    • 1
    • 3
    • 4
  • Sergei D Rybalkin
    • 5
  • Steffen Birk
    • 2
  • Ulla Engel
    • 6
  • Lars Edvinsson
    • 1
    • 7
  • Jes Olesen
    • 2
  1. 1.Department of Clinical Experimental Research, Glostrup HospitalUniversity of CopenhagenGlostrupDenmark
  2. 2.Danish Headache Center and Department of Neurology, Glostrup HospitalUniversity of CopenhagenGlostrupDenmark
  3. 3.Department of Clinical Biochemistry, Glostrup HospitalUniversity of CopenhagenGlostrupDenmark
  4. 4.Department of Physiology & Pennsylvania Muscle InstituteUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.Dept. of PharmacologyUniversity of WashingtonSeattleUSA
  6. 6.Department of PathologyHillerod HospitalHillerodDenmark
  7. 7.Division of Experimental Vascular Research, Department of Internal MedicineUniversity Hospital of LundLundSweden

Personalised recommendations